Jeuveau®

Jeuveau® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).Finger pointing to vial of Jeuveau with Cibolo Creek Dermatology Group logo

Modern-made using Hi-Pure™ Technology. Jeuveau® stops your nerves from telling your facial muscles to flex, temporarily smoothing moderate to severe lines between the brows.

Jeuveau® dosing units are not the same as, or comparable to, any other botulinum.

JEUVEAU® BEFORE and AFTER

White woman frowning

BEFORE

*JEUVEAU® patient at maximum frown. Individual results may vary

White woman frowning
White woman frowning

AFTER (Day 2)

In a study conducted in Europe and Canada, 54% of patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).1 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).2 Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

White woman frowning
White woman frowning

AFTER (Day 30)

In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively, compared to 1% for placebo.

*JEUVEAU® patient at maximum frown. Individual results may vary

White woman frowning
White woman frowning

AFTER (Day 150)

In a study conducted in Europe and Canada, 38% of patients had a ≥1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint).1 In US studies, almost 5% of patients had a ≥2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint).2 Results after day 30 or based on a 1-grade improvement may not be clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

White woman frowning
Black woman frowning

BEFORE

*JEUVEAU® patient at maximum frown. Individual results may vary

Black woman frowning
Black woman frowning

AFTER (Day 2)

In a study conducted in Europe and Canada, 54% of patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).1 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).2 Results based on a 1-grade improvement may not be considered clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Black woman frowning
Black woman frowning

AFTER (Day 30)

In two US studies, the overall efficacy of Jeuveau® was evaluated using a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30 at 68% and 70%, respectively, compared to 1% for placebo.

*JEUVEAU® patient at maximum frown. Individual results may vary

Black woman frowning
Black woman frowning

AFTER (Day 150)

In a study conducted in Europe and Canada, 38% of patients had a ≥1-grade improvement in frown lines at 5 months based on physician assessment compared to 8% for placebo (secondary endpoint).1 In US studies, almost 5% of patients had a ≥2-grade improvement in frown lines at 5 months based on both patient and physician assessments compared to 0% for placebo (secondary endpoint).2 Results after day 30 or based on a 1-grade improvement may not be clinically meaningful.

*JEUVEAU® patient at maximum frown. Individual results may vary

Black woman frowning

Call us today at (830) 971-5256 for more information about pricing or request an appointment online.